FY 2018 nearing an end - Year of the NDA submission and Vivagel negotiations.
FY 2019 - Year of the Vivagel milestone payments and entry into a few territories. I expect wild share price fluctuations.
FY 2020 - Year of the Vivagel revenue when we may actually see a reasonable valuation for Starpharma.
The Astrazenica partnership and other DEP developments could take us on a turbulent SP journey over this period.
DYOR, my thoughts only.
SPL Price at posting:
$1.26 Sentiment: Hold Disclosure: Held
